We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Ampronix,  Inc

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Cannabis Inhaler Could Spread Use of Medical Marijuana

By HospiMedica International staff writers
Posted on 25 May 2015
Print article
Image: The Syqe Exo Inhaler device (Photo courtesy of Syqe Medical).
Image: The Syqe Exo Inhaler device (Photo courtesy of Syqe Medical).
An innovative portable thermal-metered-dose inhaler (tMDI) for Cannabis provides doctors with the ability to supervise the medical marijuana process.

The Syqe Inhaler is a pocket-sized device that utilizes selective dosing, real-time thermal and flow controllers, lung interfacing, and wireless connectivity to deliver a metered dose of tetrahydrocannabinol (THC), allowing patients to reach an optimum balance between symptom relief and psychoactivity. The platform is further comprised of proprietary raw Cannabis structural-modification methods, uniquely identified preloaded cartridges, and a linked clinical database that serves physicians, researchers, and healthcare entities.

Also available is the Syqe Inhaler Exo, which delivers a fixed 100 microgram dose of Cannabis for professional healthcare use. The Exo features a caregiver interface for nurses and other certified caregivers in hospital pain clinics, cancer centers, intensive care units (ICUs), and other medical institutions. Both inhalers differ from traditional vaporizers by using granules that contain standardized portions of whole Cannabis, in sizes as small as 1 mg. Device connectivity further helps monitor use and determine best dosages for different conditions.

Uniquely, 75% of the parts of the Syqe Inhaler prototype devices were printed on Stratasys (Rehovot, Israel) three dimensional (3D) printers, a convenience that sped up the manufacturing process. The Syqe Inhaler and the Syqe Inhaler Exo are products of Syqe Medical (Tel Aviv, Israel) and have been authorized for use in Israel since October 2014.

“Different materials were selected for the four main components of the device - the shell, chassis, airway, and thermal housing, which allowed them to have rigidity, clarity, biocompatibility, and heat resistance for the inhaler,” said Perry Davidson, CEO of Syqe Medical. “Since metered dose inhalation of raw botanicals is a highly unconventional undertaking, we had to develop the tooling and machines for many of our processes. More than half of our production equipment, jigs, and analytical tools were printed in house.”

Related Links:

Syqe Medical



Print article

Channels

Copyright © 2000-2020 Globetech Media. All rights reserved.